Blueprint Medicines Corporation (NASDAQ:BPMC) Director Daniel Lynch sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $60.00, for a total value of $150,000.00. Following the sale, the director now owns 209,342 shares of the company’s stock, valued at approximately $12,560,520. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Daniel Lynch also recently made the following trade(s):
- On Wednesday, July 5th, Daniel Lynch sold 7,500 shares of Blueprint Medicines Corporation stock. The shares were sold at an average price of $55.06, for a total value of $412,950.00.
- On Wednesday, June 28th, Daniel Lynch sold 32,500 shares of Blueprint Medicines Corporation stock. The shares were sold at an average price of $50.28, for a total value of $1,634,100.00.
Shares of Blueprint Medicines Corporation (BPMC) traded up 0.687% on Thursday, hitting $62.285. The stock had a trading volume of 164,012 shares. The firm’s 50-day moving average is $50.77 and its 200 day moving average is $45.84. Blueprint Medicines Corporation has a 1-year low of $25.08 and a 1-year high of $64.98. The stock’s market cap is $2.44 billion.
Blueprint Medicines Corporation (NASDAQ:BPMC) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.11). Blueprint Medicines Corporation had a negative return on equity of 45.58% and a negative net margin of 388.91%. The business had revenue of $5.89 million for the quarter, compared to analyst estimates of $5.96 million. During the same period in the prior year, the firm posted ($0.70) EPS. Blueprint Medicines Corporation’s revenue for the quarter was down 16.7% on a year-over-year basis. Equities analysts forecast that Blueprint Medicines Corporation will post ($3.59) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.themarketsdaily.com/2017/09/21/blueprint-medicines-corporation-bpmc-director-daniel-lynch-sells-2500-shares-of-stock.html.
Institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its stake in Blueprint Medicines Corporation by 68.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 1,391 shares during the period. Fred Alger Management Inc. bought a new position in Blueprint Medicines Corporation during the second quarter valued at about $203,000. SG Americas Securities LLC increased its stake in Blueprint Medicines Corporation by 23.3% during the second quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 778 shares during the period. BNP Paribas Arbitrage SA increased its stake in Blueprint Medicines Corporation by 4,457.0% during the second quarter. BNP Paribas Arbitrage SA now owns 4,238 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 4,145 shares during the period. Finally, Amalgamated Bank bought a new position in Blueprint Medicines Corporation during the second quarter valued at about $232,000. Hedge funds and other institutional investors own 90.71% of the company’s stock.
A number of equities research analysts have weighed in on BPMC shares. Canaccord Genuity set a $52.00 price objective on Blueprint Medicines Corporation and gave the company a “buy” rating in a research note on Tuesday, June 6th. Zacks Investment Research lowered Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $79.00 price objective (up previously from $64.00) on shares of Blueprint Medicines Corporation in a research note on Wednesday. Wedbush restated an “outperform” rating and set a $55.00 price objective on shares of Blueprint Medicines Corporation in a research note on Tuesday, June 6th. Finally, BidaskClub lowered Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 19th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $54.40.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.